Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15754334 | 1.00 | MMP2 (0.57) | MMP2OPRK1CTSCGNPATCALCRL | |
| SCHEMBL9450568 | 0.93 | CTSC (0.54) | MMP2OPRK1CTSCERAP2LNPEP | |
| SCHEMBL27584126 | 0.88 | GHSR (0.53) | MMP2OPRK1GNPAT | |
| SCHEMBL27584132 | 0.88 | GHSR (0.53) | MMP2OPRK1GNPAT | |
| SCHEMBL31408938 | 0.88 | MMP2 (0.62) | MMP2OPRK1GNPATCALCRLNPY1R | |
| SCHEMBL34464901 | 0.88 | MMP2 (0.62) | MMP2OPRK1GNPATCALCRLNPY1R | |
| SCHEMBL9132107 | 0.87 | CTSC (0.60) | MMP2OPRK1CTSCLTA4HERAP2 | |
| SCHEMBL2196618 | 0.87 | CTSC (0.60) | MMP2OPRK1CTSCLTA4HERAP2 | |
| SCHEMBL6380974 | 0.87 | MMP2 (0.62) | MMP2CTSCLTA4HERAP2LNPEP | |
| SCHEMBL10633263 | 0.87 | CTSC (0.60) | MMP2OPRK1CTSCLTA4HERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION | 2022-06-09 | — | — | US | claimed |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | OHIO STATE INNOVATION FOUNDATION (US) | 2018-10-16 | — | — | US | claimed |
| US-20180185502-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION | 2018-07-05 | — | — | US | claimed |
| WO-2017172881-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-05 | — | — | WO | claimed |
| WO-2016210141-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2016-12-29 | — | — | WO | claimed |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2014-06-05 | — | — | US | claimed |
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION | 2022-06-09 | — | — | US | disclosed |
| US-20190083574-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | OHIO STATE INNOVATION FOUNDATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180185502-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION | 2018-07-05 | — | — | US | disclosed |
| WO-2017172881-A1 | THERMOGENIC COMPOSITIONS AND METHODS | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2016210141-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | OHIO STATE INNOVATION FOUNDATION (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185502-A1 | IMMOBILIZATION OF BIOMOLECULES BY SELF-ASSEMBLED NANOSTRUCTURES | CA1, CPN1, CA7 | MMP2 45/4885OPRK1 4602/4885CTSC 138/4885 |
| US-20220175872-A1 | THERMOGENIC COMPOSITIONS AND METHODS | LRBA, IAPP, FABP4 | MMP2 370/4885OPRK1 612/4885CTSC 216/4885 |
| US-20140155577-A1 | SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES | IAPP, TAP1, LNPEP | MMP2 1018/4885OPRK1 2682/4885CTSC 374/4885 |
| US-10098967-B2 | Self-assembly of therapeutic agent-peptide nanostructures | IAPP, NPPA, TAP1 | MMP2 1614/4885OPRK1 3129/4885CTSC 508/4885 |
| US-20190083574-A1 | THERMOGENIC COMPOSITIONS AND METHODS | LRBA, IAPP, FABP4 | MMP2 370/4885OPRK1 612/4885CTSC 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.